Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 82

1.

The strategy of immunologic control of HIV-1 with structured treatment interruptions (STIs).

Moss RB, Jensen FC, Carlo DJ, Wallace MR.

Curr Drug Targets Infect Disord. 2001 May;1(1):11-7. Review.

PMID:
12455230
2.

Expression of perforin on HIV-1-specific CD8+ lymphocytes after immunization with a gp120-depleted, whole-killed HIV-1 immunogen.

Moss RB, Giermakowska WK, Wallace MR, Jensen FC, Maigetter RZ, Carlo DJ.

Clin Exp Immunol. 2001 May;124(2):248-54.

4.

HIV-Specific CD4(+) and CD8(+) immune responses are generated with a gp120-depleted, whole-killed HIV-1 immunogen with CpG immunostimulatory sequences of DNA.

Moss RB, Diveley J, Jensen FC, Gouveia E, Savary J, Carlo DJ.

J Interferon Cytokine Res. 2000 Dec;20(12):1131-7.

PMID:
11152580
5.
6.

Adjuvant activity of incomplete Freund's adjuvant.

Jensen FC, Savary JR, Diveley JP, Chang JC.

Adv Drug Deliv Rev. 1998 Jul 6;32(3):173-186.

PMID:
10837643
7.

Insights into HIV-specific immune function: implications for therapy and prevention in the new millennium.

Moss RB, Jensen FC, Carlo DJ.

Clin Immunol. 2000 May;95(2):79-84. Review. No abstract available.

PMID:
10779400
8.

CXCR4 and CCR5 expression on CD4+ T cells in vivo and HIV-1 antigen beta-chemokine production in vitro after treatment with HIV-1 immunogen (REMUNE).

Moss RB, Giermakowska WK, Diveley JP, Savary JR, Wallace MR, Maigetter RZ, Jensen FC, Carlo DJ.

J Hum Virol. 2000 Jan-Feb;3(1):44-9.

PMID:
10774806
9.

Cell-mediated immune responses to autologous virus in HIV-1-seropositive individuals after treatment with an HIV-1 immunogen.

Moss RB, Giermakowska WK, Wallace MR, Savary JR, Jensen FC, Carlo DJ.

AIDS. 2000 Nov 10;14(16):2475-8.

PMID:
11101057
10.

Phenotypic analysis of human immunodeficiency virus (HIV) type 1 cell-mediated immune responses after treatment with an HIV-1 immunogen.

Moss RB, Wallace MR, Giermakowska WK, Webb E, Savary J, Chamberlin-Brandt C, Theofan G, Musil R, Richieri SP, Jensen FC, Carlo DJ.

J Infect Dis. 1999 Sep;180(3):641-8.

PMID:
10438350
11.

Tumor necrosis factor alpha and human immunodeficiency virus-specific functional immune responses after immunization with Gp120-depleted, inactivated HIV-1 in incomplete Freund's adjuvant (REMUNE) in HIV-1-seropositive subjects.

Moss RB, Li L, Giermakowska WK, Lanza P, Turner JL, Wallace MR, Jensen FC, Richieri SP, Daigle AE, Theofan G, Carlo DJ.

J Hum Virol. 1998 Jan-Feb;1(2):77-81.

PMID:
10195235
12.

Effect of HIV-specific immune-based therapy in subjects infected with HIV-1 subtype E in Thailand.

Churdboonchart V, Moss RB, Sirawaraporn W, Smutharaks B, Sutthent R, Jensen FC, Vacharak P, Grimes J, Theofan G, Carlo DJ.

AIDS. 1998 Aug 20;12(12):1521-7.

PMID:
9727574
13.

A primer on HIV type 1-specific immune function and REMUNE.

Moss RB, Giermakowska WK, Savary JR, Theofan G, Daigle AE, Richieri SP, Jensen FC, Carlo DJ.

AIDS Res Hum Retroviruses. 1998 Jun;14 Suppl 2:S167-75. Review.

PMID:
9672235
14.
15.

Whole-killed gp120-depleted HIV-1 antigen in a murine model for prophylactic vaccination.

Lanza P, Moss RB, Giermakowska W, Hancock RB, Richieri SP, Theofa G, Jensen FC, Salk PL, Carlo DJ.

Vaccine. 1998 Apr;16(7):727-31.

PMID:
9562693
16.

HIV-1-Specific Functional Immune Measurements as Markers of Disease Progression.

Moss RB, Richieri SP, Ferre F, Daigle AE, Trauger R, Theofan G, Giermakowska W, Lanza P, Brostoff S, Carlo DJ, Jensen FC.

J Biomed Sci. 1997 Jul-Aug;4(4):127-131.

PMID:
11725144
17.

Effect of immunization with an inactivated gp120-depleted HIV-1 immunogen on beta-chemokine and cytokine production in subjects with HIV-1 infection.

Moss RB, Trauger RJ, Giermakowska WK, Turner JL, Wallace MR, Jensen FC, Richieri SP, Ferre F, Daigle AE, Duffy C, Theofan G, Carlo DJ.

J Acquir Immune Defic Syndr Hum Retrovirol. 1997 Apr 1;14(4):343-50.

PMID:
9111476
18.

HIV type 1 isolate Z321, the strain used to make a therapeutic HIV type 1 immunogen, is intersubtype recombinant.

Choi DJ, Dube S, Spicer TP, Slade HB, Jensen FC, Poiesz BJ.

AIDS Res Hum Retroviruses. 1997 Mar 1;13(4):357-61. No abstract available.

PMID:
9071436
20.

Combination therapies against HIV-1 infection: exploring the concept of combining antiretroviral drug treatments with HIV-1 immune-based therapies in asymptomatic individuals.

Ferre F, Moss RB, Daigle AE, Trauger RJ, Richieri SP, Jensen FC, Carlo DJ.

AIDS Patient Care STDS. 1996 Dec;10(6):357-61. Review.

PMID:
11361552
21.

Viral load, CD4 percentage, and delayed-type hypersensitivity in subjects receiving the HIV-1 immunogen and antiviral drug therapy.

Moss RB, Ferre F, Levine A, Turner J, Jensen FC, Daigle AE, Richieri SP, Truckenbrod A, Trauger RJ, Carlo DJ, Salk J.

J Clin Immunol. 1996 Sep;16(5):266-71.

PMID:
8886995
22.

Initial studies on active immunization of HIV-infected subjects using a gp120-depleted HIV-1 Immunogen: long-term follow-up.

Levine AM, Groshen S, Allen J, Munson KM, Carlo DJ, Daigle AE, Ferre F, Jensen FC, Richieri SP, Trauger RJ, Parker JW, Salk PL, Salk J.

J Acquir Immune Defic Syndr Hum Retrovirol. 1996 Apr 1;11(4):351-64.

PMID:
8601221
23.

Autoproliferation in HIV-1-infected patients undergoing active HIV-1-specific immunotherapy.

Trauger RJ, Giermakowska W, Wormsley S, Turner J, Jensen FC, Carlo DJ.

Clin Exp Immunol. 1995 Apr;100(1):7-12.

24.

Effect of immunization with inactivated gp120-depleted human immunodeficiency virus type 1 (HIV-1) immunogen on HIV-1 immunity, viral DNA, and percentage of CD4 cells.

Trauger RJ, Ferre F, Daigle AE, Jensen FC, Moss RB, Mueller SH, Richieri SP, Slade HB, Carlo DJ.

J Infect Dis. 1994 Jun;169(6):1256-64.

PMID:
7910836
25.
26.

Lipid composition and fluidity of the human immunodeficiency virus envelope and host cell plasma membranes.

Aloia RC, Tian H, Jensen FC.

Proc Natl Acad Sci U S A. 1993 Jun 1;90(11):5181-5.

27.

T cell receptor V beta repertoire in HIV-infection individuals: lack of evidence for selective V beta deletion.

Boyer V, Smith LR, Ferre F, Pezzoli P, Trauger RJ, Jensen FC, Carlo DJ.

Clin Exp Immunol. 1993 Jun;92(3):437-41.

28.

Cell-mediated immunity to HIV-1 in Walter Reed stages 1-6 individuals: correlation with virus burden.

Trauger RJ, Giermakowska WK, Ferre F, Duffy PC, Wallace MR, Lewis DE, Beecham HJ, Burnett KG, Jensen FC, Carlo DJ.

Immunology. 1993 Apr;78(4):611-5.

29.

Quantitation of HIV viral burden by PCR in HIV seropositive Navy personnel representing Walter Reed stages 1 to 6.

Ferre F, Marchese A, Duffy PC, Lewis DE, Wallace MR, Beecham HJ, Burnett KG, Jensen FC, Carlo DJ.

AIDS Res Hum Retroviruses. 1992 Feb;8(2):269-75.

PMID:
1540412
30.

Observations after human immunodeficiency virus immunization and challenge of human immunodeficiency virus seropositive and seronegative chimpanzees.

Gibbs CJ Jr, Peters R, Gravell M, Johnson BK, Jensen FC, Carlo DJ, Salk J.

Proc Natl Acad Sci U S A. 1991 Apr 15;88(8):3348-52.

31.

Thermotropic lipid phase separation in the human immunodeficiency virus.

Gordon LM, Jensen FC, Curtain CC, Mobley PW, Aloia RC.

Biochim Biophys Acta. 1988 Aug 18;943(2):331-42.

PMID:
2840961
32.

Lipid composition and fluidity of the human immunodeficiency virus.

Aloia RC, Jensen FC, Curtain CC, Mobley PW, Gordon LM.

Proc Natl Acad Sci U S A. 1988 Feb;85(3):900-4.

33.

Spontaneous remission of Kaposi's sarcoma in an HTLV-III-negative homosexual man.

Blayney DW, Ito JI, Jensen FC.

Cancer. 1986 Oct 1;58(7):1583-4.

PMID:
3017541
34.

Leukopenic chronic T cell leukemia mimicking hairy cell leukemia: association with human retroviruses.

Sohn CC, Blayney DW, Misset JL, Mathé G, Flandrin G, Moran EM, Jensen FC, Winberg CD, Rappaport H.

Blood. 1986 Apr;67(4):949-56.

35.

Persistent infection of chimpanzees with human T-lymphotropic virus type III/lymphadenopathy-associated virus: a potential model for acquired immunodeficiency syndrome.

Fultz PN, McClure HM, Swenson RB, McGrath CR, Brodie A, Getchell JP, Jensen FC, Anderson DC, Broderson JR, Francis DP.

J Virol. 1986 Apr;58(1):116-24.

36.

Human T-cell lymphotropic virus type-I antibodies in Falashas and other ethnic groups in Israel.

Ben-Ishai Z, Haas M, Triglia D, Lee V, Nahmias J, Bar-Shany S, Jensen FC.

Nature. 1985 Jun 20-26;315(6021):665-6.

PMID:
2989699
37.

Production and characterization of monoclonal antibody to gentamicin.

Place JD, Thompson SG, Burd JF, Molinaro C, Ott RA, Jensen FC.

Hybridoma. 1984 Summer;3(2):187-93.

PMID:
6480024
38.

Amplification of the murine leukemia virus Mr 70,000 glycoprotein gene product by human xenografts in athymic mice.

Beattie GM, Lannom RA, Baird SM, Helsell EV 3rd, Jensen FC, Leis JF, Kaplan NO.

Cancer Res. 1983 Sep;43(9):4349-54.

39.

Gentamicin substrate-labeled fluorescent immunoassay containing monoclonal antibody.

Place JD, Thompson SG, Clements HM, Ott RA, Jensen FC.

Antimicrob Agents Chemother. 1983 Aug;24(2):246-51.

41.

Induction of sarcomas in athymic mice.

Beattie GM, Knowles AF, Jensen FC, Baird SM, Kaplan NO.

Proc Natl Acad Sci U S A. 1982 May;79(9):3033-6.

42.

Anti-RNP monoclonal antibodies derived from a mouse strain with lupus-like autoimmunity.

Billings PB, Allen RW, Jensen FC, Hoch SO.

J Immunol. 1982 Mar;128(3):1176-80.

PMID:
6173424
43.

Induction of lymphoma in antigenically stimulated athymic mice.

Baird SM, Beattie GM, Lannom RA, Lipsick JS, Jensen FC, Kaplan NO.

Cancer Res. 1982 Jan;42(1):198-206.

44.

IgG and IgM antibodies to rubella quantitated by enzyme immunoassay.

Johnson RB Jr, Jensen FC, Peter CR, Nakamura RM.

J Immunoassay. 1982;3(2):197-222.

PMID:
6762381
45.

Low-calorie diet selectively reduces expression of retroviral envelope glycoprotein gp70 in sera of NZB x NZW F1 hybrid mice.

Izui S, Fernandes G, Hara I, McConahey PJ, Jensen FC, Dixon FJ, Good RA.

J Exp Med. 1981 Oct 1;154(4):1116-24.

47.

Induction of high serum levels of retroviral env gene products (gp70) in mice by bacterial lipopolysaccharide.

Hara I, Izui S, McConahey PJ, Elder JH, Jensen FC, Dixon FJ.

Proc Natl Acad Sci U S A. 1981 Jul;78(7):4397-401.

48.

Immunochemical delineation of an oncofetal antigen on normal and simian virus 40-transformed human fetal melanocytes.

Morgan AC Jr, Galloway DR, Jensen FC, Giovanella BC, Reisfeld RA.

Proc Natl Acad Sci U S A. 1981 Jun;78(6):3834-8.

49.

Structural diversity among retroviral gene products: a molecular approach to the study of biological function through structural variability.

Gautsch JW, Elder JH, Jensen FC, Lerner RA.

Adv Cancer Res. 1981;34:171-209. Review. No abstract available.

PMID:
6269371
50.

Induction of lymphoma in athymic mice: a model for study of the human disease.

Beattie G, Baird S, Lannom R, Slimmer S, Jensen FC, Kaplan NO.

Proc Natl Acad Sci U S A. 1980 Aug;77(8):4971-4.

Supplemental Content

Loading ...
Support Center